Achieving Flexibility In T Cell Manufacturing - Adaptation Of Standardized Processes

Over the past decade, CAR-T therapy has evolved rapidly, driven by the need to streamline manufacturing and reduce costs without compromising efficacy. Each step—from cell isolation and T-cell activation to genetic modification and expansion—requires a deep understanding of how T cell biology responds to process changes. As therapies scale to meet allogeneic demands, maintaining consistency and potency becomes increasingly complex. This webinar explores how the standardized T Cell Transduction (TCT) process, performed on the CliniMACS Prodigy® platform, supports scalable manufacturing while preserving critical cell characteristics. Gain insights into how different manufacturing modalities impact T cell function and how the TCT process can be adapted to meet diverse production needs.